Purpose: We evaluated the use of abiraterone acetate (1,000 mg) plus prednisone (5 mg) in patients with high risk, nonmetastatic, castration resistant prostate cancer. Materials and Methods: Patients considered at high risk for progression to metastatic disease (prostate specific antigen 10 ng/ml or greater, or prostate specific antigen doubling time 10 months or less) received abiraterone acetate plus prednisone daily in 28-day cycles. The primary study end point was the proportion of patients in whom a 50% or greater prostate specific antigen reduction was achieved during cycles 1 to 6. Secondary end points included time to prostate specific antigen progression, time to radiographic evidence of disease progression and safety. Results: Of the 131 enrolled patients 44 (34%) remained on treatment with a median followup of 40.0 months. Median age was 72 years (range 48 to 90). Of the patients 82.4% were white and 14.5% were black. Median screening prostate specific antigen was 11.9 ng/dl and median prostate specific antigen doubling time was 3.4 months. Prostate specific antigen was significantly reduced (p <0.0001) with a 50% or greater prostate specific antigen reduction in 86.9% of cases and a 90% or greater reduction in 59.8%. Median time to prostate specific antigen progression was 28.7 months (95% CI 21.2e38.2). Median time to radiographic evidence of disease progression was not reached but on sensitivity analysis in 15 patients it was estimated to be 41.4 months (95% CI 27.6enot estimable). Baseline testosterone 12.5 ng/dl or greater and a 90% or greater prostate specific antigen reduction at cycle 3 were associated with longer time to Accepted for publication March 31, 2018. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
prostate specific antigen progression and radiographic evidence of disease progression. Outcomes in black patients were similar to those in other patients. Adverse events, grade 3 or greater adverse events and serious adverse events were reported in 96.2%, 61.1% and 43.5% of patients, respectively. Conclusions: In patients with high risk, nonmetastatic, castration resistant prostate cancer treatment with abiraterone acetate plus prednisone demonstrated a significant 50% or greater prostate specific antigen reduction with encouraging results for the secondary end points, including the safety of 5 mg prednisone.
Key Words: prostatic neoplasms, abiraterone acetate, prednisone, prostate-specific antigen, adverse events ABIRATERONE acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor which blocks 17a hydroxylase/C17,20-lyase, thus decreasing levels of testosterone produced by the testes, the adrenal glands and prostate cancer tissue. Abiraterone acetate with 10 mg prednisone was approved by the United States FDA to treat patients with mCRPC and patients with metastatic, high risk, castration sensitive prostate cancer. 1 The magnitude of the benefit measured by time to radiographic progression in patients before vs after chemotherapy (16.5 vs 5.6 months) as well as PSA50 (62% vs 29%) 2, 3 suggested that patients treated earlier in disease progression may derive a greater disease progression benefit.
At the time that this study was initiated there were no currently approved effective treatments for patients with high risk nmCRPC. Two prospective, randomized, controlled trials, including 1 of apalutamide and 1 of enzalutamide, revealed positive results with significant prolongation in time to MFS in February 2018. 4, 5 To our knowledge only apalutamide has received FDA approval to date for the treatment of patients with nmCRPC. 4e6 We present the results of this phase 2 proof of concept study, IMAAGEN.
MATERIALS AND METHODS

Study Design and Treatment
IMAAGEN (ClinicalTrials.gov NCT01314118) is a phase 2, multicenter, open label, single arm study. This study was institutional review board approved and all patients provided written informed consent. Patients were enrolled from April 2011 to July 2013. After meeting all other entry criteria, including PSADT 10 months or less, or absolute PSA 10 ng/ml or greater, patients underwent technetium bone scan as well as CT or MRI to confirm nonmetastatic status. Unless orchiectomy had been done the enrolled patients continued on androgen deprivation therapy and received once daily, orally administered AA 1,000 mg and prednisone 5 mg in customary 28-day treatment cycles.
This study was only statistically powered for the primary end point of the proportion of patients who achieved PSA50 during cycles 1 to 6. Secondary end points were time to PSA progression; time to radiographic evidence of disease progression; the proportion of patients who achieved a 30% or greater, 50% or greater, or 90% or greater reduction in PSA by the end of cycle 6; the proportion of patients who achieved PSA50 by the end of cycle 3; changes in PSA with time, and in baseline and testosterone levels after cycles 3 and 6; the change from baseline and safety.
AEs were assessed using the NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events), version 4.03. All study laboratory assessments were performed at a central laboratory. Efficacy was assessed by PSA and testosterone levels as well as imaging studies (bone scans and CT or MRI of the chest, abdomen and pelvis) at baseline, after cycles 3 and 6, and every 2 and 3 cycles thereafter for PSA and imaging, respectively.
In patients with imaging studies suspicious for radiographic progression of disease confirmatory imaging was planned 6 to 8 weeks later according to PCWG2 7 guidance. Time to radiographic progression of disease was considered the time between the initiation of AAþP and the time to the first scan showing disease progression according to the modified RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria. Time to PSA progression was considered the time between the initiation of AAþP and the time that a 25% or greater increase and a 2 ng/ml or greater absolute increase in PSA from nadir occurred, as confirmed by a second PSA measurement 3 weeks or later thereafter as outlined by the PCWG2. 7 Following achievement of the primary end point, which was first reported at ASCOÒ (American Society of Clinical Oncology) 2014, data have been updated and reported annually.
8e10 Results in the current series are through the data cutoff of October 13, 2015, after which the study was amended to allow for patients without progression to continue to receive treatment. However, central laboratory and imaging requirements were removed and the study is ongoing.
Key Eligibility Criteria
Men 18 years old or older who had confirmed nmCRPC, a screening serum testosterone level less than 50 ng/dl or less than 2.0 nM and rising PSA (PSA 10 ng/ml or greater at screening or PSADT 10 months or less) were enrolled in study. Patients with local disease progression or metastatic disease according to modified RECIST criteria or who had received chemotherapy for CRPC, prior therapy with aminoglutethimide or ketoconazole, or current antiandrogen therapy were excluded from study.
Statistical Analyses
Efficacy end points were analyzed in the efficacy evaluable population, defined as patients who completed 1 or more treatment cycles with 75% or greater treatment compliance with AAþP and underwent 1 or more postbaseline PSA assessments. The primary end point was analyzed using a normal approximation to the binomial distribution compared with the observed proportion to a referent of 0.35.
Time to PSA progression and time to radiographic evidence of disease progression were summarized using the Kaplan-Meier method. After a median 40 months of followup some patients withdrew from study due to suspected disease progression without confirmatory scans having been done. Sensitivity analysis, also using the Kaplan-Meier method, was performed to include patients in whom unconfirmed progression had led to the initiation of new therapy.
All secondary end points were summarized by descriptive statistics.
Safety variables of AEs summarized by grade which occurred within 30 days of the last dose of study drug, laboratory values, vital sign measurements and deaths reported during the study were analyzed. Safety variables were tabulated by descriptive statistics in the safety evaluable set in which all patients received study medications.
Post hoc analyses were performed to explore factors associated with response and safety. The Kaplan-Meier method was used to explore the effects of race, and baseline levels of PSA and testosterone. Landmark analyses were done to evaluate the effect of PSA reduction after 3 cycles of treatment on time to PSA progression and time to radiographic evidence of disease progression. 
RESULTS
Baseline Demographics and Disease Characteristics A total of 297 patients were screened, imaging was performed in 208 and 131 were enrolled at a total of 39 sites in the United States. A preplanned analysis was done when all enrolled patients had completed or withdrawn from the initial 6 cycles of treatment.
Of the patients 111 (85%) completed cycles 1 to 6 while 20 (15%) discontinued treatment. Study discontinuation was attributable to AEs in 6.1% of cases, disease progression in 1.5%, physician decision in 1.5%, protocol violation in 3.8% and withdrawal of consent in 2.3% ( fig. 1 ).
Of the patients 82.4% were white and 14.5% were black. Median age was 72 years (range 48 to 90) (supplementary table 1, http://jurology.com/). At the time of this data cutoff patients had received a median of 25 AAþP cycles (range 1 to 57). Median treatment duration was 22.14 months (range 0.1 to 52.0) and median followup was 40.0 months. Of the patients 44 (34%) had no evidence of disease progression and continued on treatment ( fig. 1 ).
Efficacy A 50% reduction in PSA was achieved by the end of cycle 6 in 106 patients (86.9%, 95% CI 80.9e92. 9) and in 104 (85%, 95% CI 79e92) this reduction was achieved by the end of cycle 3. Figure 2 shows the maximum PSA reductions achieved in each patient. Through cycle 6 a 30% and a 90% reduction in PSA was achieved in 111 (91%, 95% CI 86e96) and 73 patients (59.8%, 95% CI 51e69), respectively. In 27 patients (22.1%) PSA was considered undetectable at less than 0.2 ng/ml while in 7 (5.7%) PSA was less than 0.02 ng/ml (table 1) . Median time to PSA progression was 28.7 months (95% CI 21.2e38.2). Testosterone levels were reduced by approximately 96% by the end of cycle 3 and they remained so at the end of cycle 6 (table 2).
A total of 31 patients (23.7%) had confirmed radiographic evidence of disease progression based on investigator assessment. The remaining 100 patients (76.3%) were censored since they discontinued treatment prior to disease progression or continued on study without confirmed progression. At 48 months 62% of the patients were estimated to be progression-free. Median time to radiographic evidence of disease progression was not reached. However, on sensitivity analysis in 15 cases of unconfirmed progression, which led to the initiation of new therapy, the median time to radiographic evidence of disease progression was estimated to be 41.4 months (95% CI 27.6enot estimable) (table 3). Figure 3 shows the Kaplan-Meier estimates. 
Safety
Of the 131 patients 126 (96%) reported AEs, including grade 1/2 in 35% and grade 3/4 in 57%. The most common AEs were hypertension in 55 cases (42.0%), fatigue in 52 (39.4%) and hypokalemia in 44 (33.6%). In 8 patients (6.1%) study discontinuation was attributable to the AEs atrial fibrillation, acute renal failure, asthenia, mesothelioma, fatigue, dementia and increased aminotransferase.
2 Serious AEs developed in 57 patients (43.5%) (table 4). The most common serious AEs were sepsis, pneumonia and urinary retention (supplementary table 2, http://jurology.com/). Seven patients (5%) experienced AEs resulting in death. Table 5 shows AEs of special interest, which were mostly grade 1/2 events. Black patients more frequently reported an event of grade 3 hypertension (47% vs 20%). No patient discontinued AAþP due to a hypertensive event. Hypokalemia developed in 44 of the 131 patients (33.6%), which was grade 1/2 in 35 of 131 (27%). No patient discontinued AAþP due to excess mineralocorticoid or required prednisone dose escalation to manage this (supplementary table 3, http://jurology.com/).
Post Hoc Analyses
The 29 patients with baseline testosterone 12.5 ng/dl or greater experienced significantly longer time to PSA progression (p ¼ 0.03) and a nonsignificant increase in radiographic evidence of disease progression (p ¼ 0.12) compared with the 94 with baseline testosterone less than 12.5 ng/dl. The positive association between higher baseline testosterone and improved outcomes was also observed in a large, phase III, randomized, controlled study.
11
Median time to each end point was not reached in these cases. In patients with baseline testosterone less than 12.5 ng/dl median time to PSA progression was 24.9 months and median time to radiographic evidence of disease progression was 33.2 months (supplementary fig. 1 , http://jurology.com/). Landmark analyses after 3 therapy cycles and the maximum reductions in PSA were grouped into PSA reduction ranges of less than 50% in 17 patients, 50% to less than 90% in 46 and 90% or greater in 55. A greater PSA decrease was associated with prolonged time to PSA progression (median 15.7, 21.3 and 38.2 months, respectively, p ¼ 0.003) and with prolonged time to radiographic evidence of disease progression (median 14.8 and 24.8 months, and not reached, respectively, p ¼ 0.002, supplementary fig. 2 , http://jurology.com/).
The 19 black patients had baseline PSA levels which were higher than in the 112 patients of other races (median 27.8 vs 12.7 ng/ml). However, time to PSA progression (median 29.0 vs 28.6 months, p ¼ 0.57) and time to radiographic evidence of disease progression (median 41.4 months vs not reached, p ¼ 0.82) were similar to those in the other patients (supplementary fig. 3 , http://jurology.com/).
DISCUSSION
The findings of the IMAAGEN study demonstrate that a high proportion of men with nmCRPC treated with AA 1000 mg and prednisone 5 mg experienced sustained PSA reductions as well as prolonged time to radiographic evidence of metastatic disease. While 10 mg prednisone remains the standard of care when combined with AA, the administration of 5 mg of prednisone demonstrated a safety profile similar to that in earlier trials of AA using 5 or 10 mg prednisone. This trial met its goal of enrolling a percent of black men which was consistent with the general American population. 12 We also noted no difference in the overall response to treatment in black patients.
It is important to note that the IMAAGEN trial has a number of limitations. 1) There was no comparator arm, which limits the interpretation of these results. Prior studies suggest that patients with CRPC who have a lower disease burden, including those with nonmetastatic disease, experience more favorable outcomes while on androgen targeted therapy than patients with a higher burden. 13, 14 The current data are consistent with that suggestion.
2) Estimated time to metastatic progression was only reached on sensitivity analysis and it was based on only 15 patients. The PCWG2 criteria require a subsequent confirmatory scan for new lesions which develop in the first 3 to 6 months after initiating a new therapy, which are considered mCRPC. However, it is unrealistic to expect a patient to delay subsequent therapy when a first metastatic lesion appears after years of therapy. Therefore, patients with no confirmatory scans who withdrew from study due to suspected disease progression, leading to the initiation of new therapy, were included in sensitivity analyses. The median difference in the time to PSA progression and the time to radiographic evidence of disease progression was 28.7 and 41.4 months, respectively. Greater declines in the PSA response by the end of 3 months of treatment were associated with a longer time to radiographic evidence of disease progression. The question of whether the interval between PSA progression and radiographic progression was due to continued study drug efficacy could not be answered in the current analysis. However, it is useful for clinicians to understand that rising PSA does not temporally coincide with the development of radiographic evidence of metastatic disease. This study confirms that irrespective of the time between a PSA increase and radiographic progression patients should remain on therapy, as in the phase 3 studies of AAþP. 3, 15 3) There was no overall survival end point. However, since the inception of this trial, data have come to light demonstrating a strong relationship between metastasis-free and overall survival in patients with localized disease. 16 Moreover, a growing body of literature suggests the value of delaying the onset of metastatic disease in terms of physical and emotional well-being as well as cost. 17e19 4) IMAAGEN was performed using technetium bone scans and CT/MRI. With this technology 37% of these patients at high risk were found to have unsuspected metastatic disease at screening and they were not enrolled in study. 20 With the availability of newer imaging modalities such as prostate specific membrane antigen positron emission tomography, which may have higher sensitivity and specificity, and thus greater diagnostic accuracy, it is foreseeable that many more of these patients at high risk for progression to metastatic disease will be found to have radiographic evidence of metastatic disease.
Nonetheless, this does not diminish the observation that the patients in IMAAGEN had a profound PSA response and subsequent longer time to conventional radiographic evidence of disease progression than patients treated in first line mCRPC trials. For example, radiographic progression-free survival was 16.5 months compared to 8.2 months for placebo in the COU-AA-302 study of patients with mCRPC who were chemotherapy na€ ıve. 21 In fact, radiographic progression-free survival in IMAAGEN exceeded the overall survival (median 35.3 months) of patients who received AAþP in the COU-AA-302 study.
While most patients in IMAAGEN reported AEs, they were manageable. Only 6% of patients discontinued the study due to AEs by cycle 6. The full risk-benefit profile of treating patients with nmCRPC with AAþP must be further studied in a prospective, randomized, controlled trial.
CONCLUSIONS
IMAAGEN showed that treatment with AAþP demonstrated a significant reduction in PSA50 with encouraging results for the secondary end points, including the safety of 5 mg prednisone in patients with nmCRPC. These results suggest that potentially earlier treatment of CRPC with effective therapies might result in improved clinical outcomes. 
EDITORIAL COMMENTS
The IMAAGEN trial investigators report data on treating a prospective cohort of men with nonmetastatic, castration resistant prostate cancer with abiraterone plus prednisone using a reduced dose of prednisone 5 mg daily. This dose change may seem trivial but using prednisone with abiraterone is important for toxicity reduction. Abiraterone depletes testosterone by inhibiting CYP17 conversion of androgen precursors to testosterone. However, these precursors are shunted into alternative enzymatic pathways. resulting in over production of mineralocorticoid compounds, particularly corticosterone. 1 Prednisone reduces this effect by suppressing pituitary adrenocorticotropin secretion and consequently adrenal steroid production, so a reduction in the prednisone dose could increase the mineralocorticoid related adverse effects of abiraterone.
